Monoclonal antibodies remain one of the most powerful therapeutic modalities due to their high target specificity, tunable biological functions, and broad applicability across oncology, immunology, metabolic disease, and other therapeutic areas. However, successful mAb development still depends on more than generating antigen-binding molecules. Challenging targets such as membrane proteins, weakly immunogenic antigens, highly conserved proteins, and complex disease-relevant epitopes often require customized immunization strategies, efficient screening technologies, and early functional validation.

Cyagen supports monoclonal antibody programs through an integrated discovery and candidate evaluation workflow that combines tailored antigen and immunization design, hybridoma and single B cell screening, recombinant antibody expression, AbSeek™ AI-assisted sequence and developability analysis, and comprehensive functional characterization to accelerate the identification of high-affinity, functional, and development-ready monoclonal antibody candidates.